UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Choosing between equal and cap weight depends on goals and risk tolerance. This quick guide compares the two for retirement suitability.
24,468 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
As Sonida shares insights from the Q4 2025 earnings call, investors gain a clearer view of the company’s path through...
Ripple climbs about 5% to roughly $1.49, but analysts remain wary of a looming sell wall that could cap further gains.
Sri Lanka has moved to a four-day workweek, declaring Wednesdays a nationwide holiday to curb fuel use as oil shipmen...
Trinity Capital remains a high-yield fixture in venture lending, but a balance of losses, dilution, and rate shifts u...
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
A landmark innovator, Ted Turner reshaped TV by launching CNN, expanding cable, and preserving Hollywood classics. Th...
Bitcoin rebounds into the $70k-$80k zone, but pandemic-style health headlines loom over the market. Traders weigh whe...
Physical gold and silver flows to vaults and banks are accelerating in 2026, signaling potential strains on fiat curr...
Seven months into fiscal 2026, the deficit surged to $955 billion, intensifying pressure on policymakers to restrain ...
A billionaire investor backed D-Wave Quantum in late 2024, and the stock has surged and slumped in a choppy 2026 trad...
A prominent investment advisor just made a sizable play in a well-known theme park company. This article dives into t...